For patients with advanced-stage ovarian cancer, a bi-shRNAfurin/GMCSF-expressing autologous tumor cell (FANG) vaccine capable of decreasing TGFβ1/2 protein expression, was demonstrated to improve immune response and recurrence free survival in a phase II trial. The gene discussed is TGFB1; the disease is ovarian carcinoma.